Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55  years and older

ConclusionIntermediate HER2 expression is an independent predictor of poor prognosis in both ER+  EBC and MBC patients aged ≥ 55 years. The clinical efficacy of new HER2-targeting antibody–drug conjugates needs to be validated in this high-risk subset of ER+ breast cancer patients.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research